Journal article 844 views 137 downloads
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study
Diabetic Medicine, Volume: 39, Issue: 3
Swansea University Author: Steve Bain
-
PDF | Version of Record
© 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License
Download (326.57KB)
DOI (Published version): 10.1111/dme.14697
Abstract
AimsTo characterise the cardiovascular risk of people with type 2 diabetes without established cardiovascular disease but with risk factors, relative to those with established cardiovascular disease, to provide information on which patients could benefit from early use of glucose-lowering therapies...
Published in: | Diabetic Medicine |
---|---|
ISSN: | 0742-3071 1464-5491 |
Published: |
Wiley
2022
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa57800 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2021-09-07T14:32:01Z |
---|---|
last_indexed |
2022-03-17T04:25:39Z |
id |
cronfa57800 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2022-03-16T10:05:36.8887275</datestamp><bib-version>v2</bib-version><id>57800</id><entry>2021-09-07</entry><title>Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-09-07</date><deptcode>BMS</deptcode><abstract>AimsTo characterise the cardiovascular risk of people with type 2 diabetes without established cardiovascular disease but with risk factors, relative to those with established cardiovascular disease, to provide information on which patients could benefit from early use of glucose-lowering therapies that also reduce cardiovascular risk.MethodsData from people with type 2 diabetes initiating second-line glucose-lowering medication were retrieved from the UK Clinical Practice Research Datalink GOLD database and linked with Hospital Episode Statistics and Office for National Statistics (2001–2016). Cox proportional hazards models were used to estimate relative risks of major adverse cardiovascular events within groups defined by the presence of selected risk factors in people without versus with established cardiovascular disease.ResultsOf 53,182 individuals, 19.4% had established cardiovascular disease (i.e. a prior cardiovascular event). Over 5–7 years’ follow-up, the rate of major adverse cardiovascular events was 14.0 and 49.6 events/1000 person-years without and with established cardiovascular disease, respectively (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.26, 0.29). Compared with a reference HR 1.0 for participants with established cardiovascular disease, estimated glomerular filtration rate <60 ml/min was the single factor associated with the highest risk of major adverse cardiovascular events (HR 0.75, 95% CI 0.70, 0.81) and mortality (HR 1.12, 95% CI 1.07, 1.18) in people with type 2 diabetes without established cardiovascular disease. The combination of chronic kidney disease with older age, smoking and/or dyslipidaemia was associated with a similarly high risk of cardiovascular events in people with type 2 diabetes and without cardiovascular disease compared with those having established cardiovascular disease.ConclusionsThese analyses provide important information to identify people who may benefit from primary prevention of cardiovascular disease. Modifiable cardiovascular risk factors should be controlled early in all individuals with type 2 diabetes (as well as in all individuals with cardiovascular disease).</abstract><type>Journal Article</type><journal>Diabetic Medicine</journal><volume>39</volume><journalNumber>3</journalNumber><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0742-3071</issnPrint><issnElectronic>1464-5491</issnElectronic><keywords>cardiovascular disease; cardiovascular disease risk; risk factors; type 2 diabetes</keywords><publishedDay>1</publishedDay><publishedMonth>3</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-03-01</publishedDate><doi>10.1111/dme.14697</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Novo Nordisk A/S, Denmark</funders><lastEdited>2022-03-16T10:05:36.8887275</lastEdited><Created>2021-09-07T15:27:22.4111480</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Kamlesh</firstname><surname>Khunti</surname><orcid>0000-0003-2343-7099</orcid><order>1</order></author><author><firstname>Christin L.</firstname><surname>Hertz</surname><order>2</order></author><author><firstname>Lise Lotte N.</firstname><surname>Husemoen</surname><order>3</order></author><author><firstname>Emina</firstname><surname>Mocevic</surname><order>4</order></author><author><firstname>Rikke B.</firstname><surname>Nordsborg</surname><order>5</order></author><author><firstname>Johanne S.</firstname><surname>Piltoft</surname><order>6</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>7</order></author></authors><documents><document><filename>57800__21118__ba4ffa3a75864e5d97b4a9c00d533d4a.pdf</filename><originalFilename>57800.pdf</originalFilename><uploaded>2021-10-08T13:32:57.4969283</uploaded><type>Output</type><contentLength>334403</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
2022-03-16T10:05:36.8887275 v2 57800 2021-09-07 Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2021-09-07 BMS AimsTo characterise the cardiovascular risk of people with type 2 diabetes without established cardiovascular disease but with risk factors, relative to those with established cardiovascular disease, to provide information on which patients could benefit from early use of glucose-lowering therapies that also reduce cardiovascular risk.MethodsData from people with type 2 diabetes initiating second-line glucose-lowering medication were retrieved from the UK Clinical Practice Research Datalink GOLD database and linked with Hospital Episode Statistics and Office for National Statistics (2001–2016). Cox proportional hazards models were used to estimate relative risks of major adverse cardiovascular events within groups defined by the presence of selected risk factors in people without versus with established cardiovascular disease.ResultsOf 53,182 individuals, 19.4% had established cardiovascular disease (i.e. a prior cardiovascular event). Over 5–7 years’ follow-up, the rate of major adverse cardiovascular events was 14.0 and 49.6 events/1000 person-years without and with established cardiovascular disease, respectively (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.26, 0.29). Compared with a reference HR 1.0 for participants with established cardiovascular disease, estimated glomerular filtration rate <60 ml/min was the single factor associated with the highest risk of major adverse cardiovascular events (HR 0.75, 95% CI 0.70, 0.81) and mortality (HR 1.12, 95% CI 1.07, 1.18) in people with type 2 diabetes without established cardiovascular disease. The combination of chronic kidney disease with older age, smoking and/or dyslipidaemia was associated with a similarly high risk of cardiovascular events in people with type 2 diabetes and without cardiovascular disease compared with those having established cardiovascular disease.ConclusionsThese analyses provide important information to identify people who may benefit from primary prevention of cardiovascular disease. Modifiable cardiovascular risk factors should be controlled early in all individuals with type 2 diabetes (as well as in all individuals with cardiovascular disease). Journal Article Diabetic Medicine 39 3 Wiley 0742-3071 1464-5491 cardiovascular disease; cardiovascular disease risk; risk factors; type 2 diabetes 1 3 2022 2022-03-01 10.1111/dme.14697 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University Novo Nordisk A/S, Denmark 2022-03-16T10:05:36.8887275 2021-09-07T15:27:22.4111480 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Kamlesh Khunti 0000-0003-2343-7099 1 Christin L. Hertz 2 Lise Lotte N. Husemoen 3 Emina Mocevic 4 Rikke B. Nordsborg 5 Johanne S. Piltoft 6 Steve Bain 0000-0001-8519-4964 7 57800__21118__ba4ffa3a75864e5d97b4a9c00d533d4a.pdf 57800.pdf 2021-10-08T13:32:57.4969283 Output 334403 application/pdf Version of Record true © 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License true eng http://creativecommons.org/licenses/by-nc/4.0/ |
title |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study |
spellingShingle |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study Steve Bain |
title_short |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study |
title_full |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study |
title_fullStr |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study |
title_full_unstemmed |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study |
title_sort |
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study |
author_id_str_mv |
5399f4c6e6a70f3608a084ddb938511a |
author_id_fullname_str_mv |
5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain |
author |
Steve Bain |
author2 |
Kamlesh Khunti Christin L. Hertz Lise Lotte N. Husemoen Emina Mocevic Rikke B. Nordsborg Johanne S. Piltoft Steve Bain |
format |
Journal article |
container_title |
Diabetic Medicine |
container_volume |
39 |
container_issue |
3 |
publishDate |
2022 |
institution |
Swansea University |
issn |
0742-3071 1464-5491 |
doi_str_mv |
10.1111/dme.14697 |
publisher |
Wiley |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
document_store_str |
1 |
active_str |
0 |
description |
AimsTo characterise the cardiovascular risk of people with type 2 diabetes without established cardiovascular disease but with risk factors, relative to those with established cardiovascular disease, to provide information on which patients could benefit from early use of glucose-lowering therapies that also reduce cardiovascular risk.MethodsData from people with type 2 diabetes initiating second-line glucose-lowering medication were retrieved from the UK Clinical Practice Research Datalink GOLD database and linked with Hospital Episode Statistics and Office for National Statistics (2001–2016). Cox proportional hazards models were used to estimate relative risks of major adverse cardiovascular events within groups defined by the presence of selected risk factors in people without versus with established cardiovascular disease.ResultsOf 53,182 individuals, 19.4% had established cardiovascular disease (i.e. a prior cardiovascular event). Over 5–7 years’ follow-up, the rate of major adverse cardiovascular events was 14.0 and 49.6 events/1000 person-years without and with established cardiovascular disease, respectively (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.26, 0.29). Compared with a reference HR 1.0 for participants with established cardiovascular disease, estimated glomerular filtration rate <60 ml/min was the single factor associated with the highest risk of major adverse cardiovascular events (HR 0.75, 95% CI 0.70, 0.81) and mortality (HR 1.12, 95% CI 1.07, 1.18) in people with type 2 diabetes without established cardiovascular disease. The combination of chronic kidney disease with older age, smoking and/or dyslipidaemia was associated with a similarly high risk of cardiovascular events in people with type 2 diabetes and without cardiovascular disease compared with those having established cardiovascular disease.ConclusionsThese analyses provide important information to identify people who may benefit from primary prevention of cardiovascular disease. Modifiable cardiovascular risk factors should be controlled early in all individuals with type 2 diabetes (as well as in all individuals with cardiovascular disease). |
published_date |
2022-03-01T04:13:49Z |
_version_ |
1763753935817932800 |
score |
11.037603 |